Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05471856 · ClinicalTrials.gov registry record · Phase 1
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
A Phase 1 study of Solid Tumors, sponsored by Boehringer Ingelheim.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
- 13
- Study locations
NCT05471856: Recruiting Phase 1 study of Solid Tumors, sponsored by Boehringer Ingelheim.
NCT05471856 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 66 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (77% lower). The trial reports 13 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05471856, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by Boehringer Ingelheim.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study is open to adults with different types of advanced cancer. People can take part if previous treatment was not successful, or no treatment exists. The purpose of this study is to find the highest dose of a medicine called BI 1703880 that people with advanced cancer can tolerate when taken together with ezabenlimab. BI 1703880 and ezabenlimab are medicines that may help the immune system fight cancer. In this study, BI 1703880 is given to people for the first time. Participants get BI 1703880 and ezabenlimab as infusions into a vein. During the first 6 weeks, they get BI 1703880 once a week. Later, they get BI 1703880 every 3 weeks. After the first 3 weeks, they get ezabenlimab in addition every 3 weeks. Participants can get BI 1703880 for up to 1 year and ezabenlimab for up to 2 years as long as they benefit from treatment and can tolerate it. During this time, they visit the study site regularly. At these visits, the doctors check participants' health and take note of any unwanted effects.
Conditions Studied
Interventions
- DRUG BI 1703880
- DRUG Ezabenlimab
Study Locations (13)
Other
- National Cancer Center Hospital East - Chiba, Kashiwa
- Saitama Medical University International Medical Center - Saitama, Hidaka
- Japanese Foundation for Cancer Research - Tokyo, Koto-ku
- Hospital Universitari Vall D Hebron - Barcelona
- CIO Clara Campal - Madrid
- Instituto Valenciano de Oncología - Valencia
- Hospital Clinico Universitario De Valencia - Valencia
- The Royal Marsden Hospital, Chelsea - London
- Churchill Hospital - Oxford
- The Royal Marsden Hospital, Sutton - Sutton
California
- Valkyrie Clinical Trials - Los Angeles
Connecticut
- Yale University School of Medicine - New Haven
New Jersey
- John Theurer Cancer Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-02-24 |
| Est. Completion | 2028-09-13 |
| Phase | Phase 1 |
What NCT05471856 shows while recruiting
NCT05471856 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which BI 1703880 is the first listed.
NCT05471856 lists 13 locations in 4 states (Other, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT05471856 about?
NCT05471856 is a clinical study titled "A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)". This study is open to adults with different types of advanced cancer. People can take part if previous treatment was not successful, or no treatment exists. The purpose of this study is to find the highest dose of a medicine called BI 1703880 that people with advanced cancer can tolerate when taken...
What is the current status of trial NCT05471856?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2023-02-24. Estimated completion is 2028-09-13.
What conditions does trial NCT05471856 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT05471856?
The interventions under investigation include: BI 1703880 (DRUG), Ezabenlimab (DRUG).
Who is sponsoring clinical trial NCT05471856?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05471856 being conducted?
This trial has 13 study locations across California, Connecticut, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05471856's enrollment target sits among peer trials
66 67th of 125 higher than 59 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI